Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Ascortain

Approved

STANDARD

Ascortain

HIRAL LABS LIMITED🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 4dd9e4009b34ed99
Company: HIRAL LABS LIMITED
Type: Standard

Approval Details

Approval Id: 4dd9e4009b34ed99
Drug Approval Philippines Name: Ascortain
Product Name: Ascortain
Registration Number: DRP-10267
Brand Name: Ascortain
Generic Name: Ascorbic Acid
Dosage Form: Chewable Tablet (Orange Flavor)
Dosage Strength: 500 mg
Manufacturer: HIRAL LABS LIMITED
Importer: Aglobal Care, Inc.
Distributor: Aglobal Care, Inc.
Issuance Date: 26 August 2021
Expiry Date: 26 August 2026
Classification: Over-the-Counter (OTC)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

4dd9e4009b34ed99

Type

Standard

Back to Philippines FDA Approvals

Ascortain - Philippines FDA Drug Approval Details